Multiple sclerosis trials recruiting in North Carolina

All Multiple sclerosis trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
  NCT06433765 · Phase: Not specified · Ages: 15 Years to 50 Years · Sex: Female · North Carolina: Wilmington
• A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
  NCT06143514 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · North Carolina: Wilmington
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, New Bern, Raleigh
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · North Carolina: Raleigh
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
  NCT04047628 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · North Carolina: Durham
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · North Carolina: Raleigh
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · North Carolina: Charlotte, Raleigh
• Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
  NCT05658497 · Phase: Not specified · Ages: No age limits stated · Sex: Female · North Carolina: Durham
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Retinal Imaging in Neurodegenerative Disease
  NCT03233646 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  NCT05104983 · Phase: Phase 2 · Ages: 1 Day to 6 Months · Sex: All (male and female) · North Carolina: Chapel Hill
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · North Carolina: Charlotte, Raleigh